secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0000950170-24-023189
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences raises up to $124.2M in registered direct offering and private placement
--------------------------------------------------------------------------------

- $60M upfront from 13.09M shares at $4.585; warrants could add $64.2M at $4.906 exercise price.
- Preliminary cash, cash equivalents and restricted cash of $15.6M as of Dec 31, 2023.
- Net proceeds to fund cytisinicline clinical development through NDA submission expected 1H 2025.
- Warrants exercisable for 3.5 years or expire 30 days after FDA Day 74 letter acceptance; 4.99% ownership cap.
- Concurrent termination of at-the-market sales agreement with Virtu Americas LLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000095017024023189/0000950170-24-023189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000095017024023189/achv-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-023189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer